Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm.
Masahiro TakadaMasahiro SugimotoNorikazu MasudaHiroji IwataKatsumasa KuroiHiroyasu YamashiroShinji OhnoHiroshi IshiguroTakashi InamotoMasakazu ToiPublished in: Breast cancer research and treatment (2018)
The DFS and BM models have a high accuracy to predict prognosis among HER2-positive patients treated with NAC plus trastuzumab. Our models can help optimize adjuvant therapy and postoperative surveillance.
Keyphrases
- neoadjuvant chemotherapy
- free survival
- positive breast cancer
- machine learning
- patients undergoing
- epidermal growth factor receptor
- locally advanced
- lymph node
- sentinel lymph node
- metastatic breast cancer
- public health
- deep learning
- transcription factor
- resting state
- white matter
- multiple sclerosis
- functional connectivity
- early stage
- brain injury
- cerebral ischemia
- radiation therapy
- subarachnoid hemorrhage